Marc S Raab

Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple ...

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High...

Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial.

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Mul...

Elotuzumab plus VRd plus ASCT bij myeloom: GMMG-HD6 fase III

Elotuzumab plus PomDex bij recidief myeloom: ELOQUENT-3 definitieve OS

SNV's en epimutaties als resistentiemechanisme voor proteasoomremmers bij myeloom

Isatuximab plus VRd als inductie bij transplanteerbaar myeloom: GMMG-HD7 fase III

Elotuzumab plus pomalidomide-dexamethason bij multipel myeloom: ELOQUENT-3 fase II